Key Takeaways:
CG Oncology Inc. expects to report Phase 3 data for its lead oncolytic immunotherapy cretostimogene "in the coming months" and file for US approval in the fourth quarter, Chief Executive Officer Arthur said at the Goldman Sachs Global Healthcare Conference on Tuesday.
"The durability we're seeing is a key differentiator," Arthur said, citing a 46% complete response rate at 12 months and a 42% rate sustained from 12 to 24 months in BCG-unresponsive non-muscle invasive bladder cancer patients. He contrasted those figures with Merck's Keytruda, which showed a 9% complete response rate at two years, and nadofaragene firadenovec and Atevio, both in the "20% range."
Cretostimogene, an oncolytic immunotherapy administered intravesically, has demonstrated a complete response rate of more than 75% at any time in the carcinoma in situ cohort of the pivotal BOND-003 trial. The study enrolled a heavily pretreated population, including patients who had previously received chemotherapy such as gemcitabine after failing two courses of BCG therapy. Arthur said the consistent response in that group is a point the company plans to emphasize in its launch strategy.
The company is also running PIVOT-006, a randomized Phase 3 trial evaluating transurethral resection of bladder tumor with or without cretostimogene in intermediate-risk NMIBC. Enrollment of 364 patients completed in September 2025, ahead of schedule, with some months seeing 30 to 50 patients enrolled — a pace Arthur called "certainly surprising" and reflective of physician enthusiasm. An interim futility analysis was met, allowing the trial to continue. CG Oncology believes a 30% relative reduction in recurrence would be clinically meaningful, as no FDA-approved adjuvant therapy exists for this broad patient population. A BLA filing for the intermediate-risk indication is expected in 2027.
Competitive Positioning and Commercial Preparation
Bladder cancer is broadly divided into non-muscle invasive disease, representing about 80% of cases, and muscle-invasive disease at 20%. Within NMIBC, CG Oncology is targeting intermediate-risk and high-risk patients, which Arthur estimated represent about 70% of the NMIBC population. For high-risk patients who become BCG-unresponsive, the treatment goal is to prevent radical cystectomy — bladder removal surgery — and help patients preserve their bladders.
Arthur said the company has made improvements to cretostimogene's storage and delivery based on customer feedback. The product can be moved from freezer storage into a standard refrigerator at 2 to 8 degrees Celsius, where it remains stable for four to six weeks. The dwell time in clinical trials is about 15 minutes for DDM, a transduction agent used before cretostimogene, followed by up to 45 minutes to an hour for the therapy itself. Sites capable of administering BCG should generally be able to incorporate cretostimogene into existing workflows without major retraining, Arthur said.
On manufacturing, CG Oncology held a prior FDA alignment meeting focused on chemistry, manufacturing and controls and received clarity on the filing package. The company is also preparing for expected FDA inspections of manufacturing partners after filing, with particular focus on a fill-and-finish site acquired last year. Arthur said the company is "very confident" in its alignment with the FDA on analytical release testing, and that current yield and scale should cover the early years of launch.
Cash Position and Launch Planning
CG Oncology reported more than $1 billion in cash and no debt as of May 8, providing runway through 2029. Arthur said the company has not provided formal pricing guidance but noted that approved therapies range from about $260,000 to $700,000 for one year of treatment, with CG Oncology likely to be "on the right end of that spectrum." Pricing considerations are linked to the PIVOT-006 readout and the possibility of multiple indications.
For commercial infrastructure, Arthur said launch analogs point to a field force of about 50 to 75 representatives, and the company's internal analysis falls within that range. Roughly 300 network sites account for about 80% of the business opportunity, split between academic centers and community urology practices.
CG Oncology shares have gained significant ground over the past year, driven by the strength of the BOND-003 data and the potential to redefine the standard of care in a large, underserved oncology market. The company's cash position provides a cushion through multiple potential catalysts, including the PIVOT-006 readout and the Q4 BLA submission. If approved, cretostimogene would become the first oncolytic immunotherapy for bladder cancer, a market where no FDA-approved adjuvant therapy exists for intermediate-risk patients and where current options for BCG-unresponsive patients remain limited.
This article is for informational purposes only and does not constitute investment advice.
